Dr. Reddy's launches generic semaglutide Obeda in India as prices tumble

Dr. Reddy's Laboratories launched Obeda, a generic injectable semaglutide for type 2 diabetes, in India at about ₹4,200 a month, entering a market where competitors' same-day launches have already pushed some generic prices as low as ₹1,290 a month ^[1].

The company received expedited approval from the Drugs Controller General of India and began selling on the day semaglutide patent protections expired ^[1]. Obeda is available in 2 mg and 4 mg strengths in a pre-filled pen for once-weekly subcutaneous injection, and the company emphasized cold-chain integrity in the rollout ^[1]. Semaglutide is the active ingredient in Ozempic, Wegovy and Rybelsus; Obeda is a separate product from a different manufacturer. India has more than 101 million adults with diabetes, according to the launch coverage ^[1].

On the same day the patent protections lapsed, more than a dozen Indian drugmakers — among them Sun Pharmaceutical Industries, Lupin and Natco Pharma — launched their own generic semaglutide ^[1]. That wave of competing products cut prices sharply. Generic versions were available for as low as ₹1,290 a month in multi-dose vial formats, compared with innovator product prices of roughly ₹8,800 to ₹10,850 a month ^[1]. Obeda's ₹4,200 monthly price sits well above the cheapest generics, and the launch coverage said that positioning raises questions about how much market share Dr. Reddy's can capture and how well it can protect margins ^[1].

The same reporting described a market that could become more crowded still: more than 40 manufacturers could launch products under as many as 50 different brand names, which the coverage said risks rapid saturation and thinner profits for everyone ^[1]. Dr. Reddy's had a market value of about $11.54 billion and a debt-to-equity ratio of 0.18 at the time, and analyst ratings ranged from Hold to Strong Buy, according to that report ^[1]. CEO Erez Israeli has described plans to expand generic semaglutide globally under a single quality standard, and M V Ramana, CEO of Branded Markets for India and Emerging Markets, highlighted the company's aim of widening access to advanced therapies ^[1]. No quality problems specific to Dr. Reddy's were noted in connection with the launch ^[1].

Why it matters for patients

For patients in India, the practical effect is a much lower monthly cost for a medicine that mimics natural gut hormones to regulate blood sugar and appetite ^[1]. Prices like these are set in India and apply to products approved there. None of the generics described has been reported as approved or sold in the United States, and the launch coverage gives no indication that U.S. prices for Ozempic, Wegovy or Rybelsus would change because of them.

The cheapest Indian options cited are multi-dose vials rather than the pre-filled pens Obeda uses ^[1], a format difference that affects how a medicine is stored, measured and injected. Whether one generic product can substitute for another, or for a brand-name product, for a specific patient is a clinical question that pricing figures do not answer.

What happens next

Dr. Reddy's has said it intends to sell generic semaglutide in markets outside India under a unified quality standard ^[1]. Which countries it will enter, and on what timetable, has not been disclosed. Whether the Indian prices cited at launch have held or fallen further since has not been reported.